Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. de Biase D, et al. Among authors: degli esposti r. PLoS One. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PLoS One. 2017. PMID: 28520821 Free PMC article.
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Genestreti G, de Biase D, Di Battista M, Cavallo G, Degli Esposti R, Visani M, Acquaviva G, Brand T, Pession A, Tallini G, Brandes AA. Genestreti G, et al. Among authors: degli esposti r. Clin Lung Cancer. 2017 May;18(3):e215-e217. doi: 10.1016/j.cllc.2017.01.003. Epub 2017 Jan 11. Clin Lung Cancer. 2017. PMID: 28162944 No abstract available.
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, Silini EM, Campanini N, Barbieri E, Zamagni C, Degli Esposti R, Cortesi L, Bisagni G, Cavanna L, Frassoldati A, Sgargi P, Michiara M. Musolino A, et al. Among authors: degli esposti r. Eur J Cancer. 2018 Jan;88:10-20. doi: 10.1016/j.ejca.2017.10.024. Epub 2017 Nov 23. Eur J Cancer. 2018. PMID: 29175735
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF, Donati S, Gennari A, Guarneri V, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato AG, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L. Conte PF, et al. Among authors: degli esposti r. Br J Cancer. 2005 Aug 22;93(4):406-11. doi: 10.1038/sj.bjc.6602723. Br J Cancer. 2005. PMID: 16052214 Free PMC article. Clinical Trial.